Skip to main content
TipRanks
Go Ultimate75% OFF

Acrux (ARUXF) AI Stock Analysis

4 Followers
ARUXF

Acrux

(Other OTC:ARUXF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue reboundThe strong 2026 revenue rebound indicates that Acrux retained the ability to generate materially higher sales after a difficult period. If maintained, improved commercial traction could support operating leverage, strengthen cash generation, and provide a better base for future product development.
Negative Factors
Persistent unprofitabilityPersistent net, EBIT, and EBITDA losses indicate that Acrux has not yet demonstrated a sustainable profit engine. Continued operating losses can consume financial resources, constrain investment in its topical drug pipeline, and make future growth more dependent on uncertain revenue improvement or funding.

Acrux (ARUXF) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%ARUXF+100.00%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.41M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-7.1
Beta (1Y)
0.32
Revenue Growth
319.51%
EPS Growth
91.30%
Country
US
Employees
43
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Acrux Business Overview & Revenue Model

Company Description

Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international...

Acrux Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ARUXF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:CUVAU:CUV77OutperformAUD 372.59M10.6013.00%0.69%-1.05%-6.74%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:SPLAU:SPL43NeutralAUD 205.24M-24.27-42.35%―145.32%25.75%
AU:TRPAU:TRP40UnderperformAUD 5.86M-1.24-52.04%―32.22%-26.53%
AU:CMBAU:CMB39UnderperformAUD 10.30M-1.39-247.44%―-4.24%33.39%
AU:BOTAU:BOT38UnderperformAUD 27.63M-0.28-118.74%―499.47%31.20%

* Healthcare Sector Average

Performance Comparison

0%100%200%ARUXFAU:CUVAU:SPLAU:TRPAU:CMBAU:BOTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ARUXF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ARUXFAcrux Limited0.020.01100.00%
AU:CUVClinuvel Pharmaceuticals Limited7.29-3.57-32.90%
AU:SPLStarpharma Holdings Limited0.420.036.52%
AU:TRPTissue Repair Ltd0.11-0.19-63.33%
AU:CMBRegeneus Ltd.0.35-0.16-31.37%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.11-91.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.